

Comparison of Dissolution Profiles of Furosemide Tablets Available in the Argentinian Market

Yong K. Han, Laura D. Simionato, Romina G. Calvo, María B. Mattei and Adriana I. Segall*

Cátedra de Calidad de Medicamentos, Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires, CONICET, Junín 956 (1113) CABA, Argentina

Abstract: In this work dissolution profiles of furosemide tablets of nine commercial products marketed in Argentina were evaluated. All brands fulfill the specifications of dissolution test of USP. Comparison of dissolution profiles were carried out by model-dependent and model independent approaches. Results obtained *via* model-dependent approach show a first order drug release mechanism especially for Brand I (reference) and Brand IV. Results obtained *via* model-independent approach show that there was not significant difference in Dissolution efficiency between the reference product and Brands II, III and IV and in Mean dissolution time between the reference product and Brands II, III, IV and V. Using fit factors, only Brands I and III were similar.

Keywords: Furosemide, tablets, dissolution profiles, commercial products, model-dependent, model-independent.

INTRODUCTION

The rate and the extent of drug dissolution and its absorption depend on the characteristics of the active pharmaceutical ingredient (API) as well as the dosage form properties. Since an orally administered drug must be in solution in order to be absorbed in the gastro intestinal tract and to reach the systemic circulation, the dosage form plays an important role in condition the absorption rate [1].

Dissolution test are widely used in the pharmaceutical industry for developing new drug products, determining the long-term stability and shelf life of a dosage form and assessing the impact of post-approval changes in the manufacturing process. In the case of immediate-release solid dosage forms such as tablets, dissolution test are used to evaluate batches and can be used to evaluate new and existing formulations and possibly to assess the impact of certain changes in the formulation and manufacturing process [2]. Based on these consideration, dissolution test are largely used to assure the quality of the pharmaceutical product. Due to economic reasons, the use of generic medicines has been given much incentive by health authorities through the world. In our Country, there is a Disposition of our Health Authorities to evaluate bioavailability and bioequivalence of the market pharmaceutical products containing Furosemide [3]. Up to now, there have been no studies about bioavailability and bioequivalence of the marketed products.

Furosemide, 4-chloro-2-[(2-furanylmethyl)-amino]-5-sulfamoylbenzoic acid, is a loop diuretic that is used orally in the treatment of edematous states associated with cardiac, renal, and hepatic failure and the treatment of hypertension. The usual dose is 40-120 mg/day. Furosemide is a weak acid with an acidic pKa value of 3.8 (carboxylic acid). Seven polymorphic forms are known: four true polymorphs (I, II, III, and IV), two solvates (IV-DMS and V-dioxane) and one amorphous form but polymorph-dependent bioavailability has not been reported to date in the literature [4].

The available data on solubility, oral absorption, and permeability are sufficiently to classify furosemide into Class IV of the Biopharmaceutics Classification System (BCS4) [4]. A number of investigations have been done to improve furosemide solubility which can significantly increase its *in vitro* dissolution rate [5-16].

Although immediate release solid dosage forms are routinely subjected to test such as content uniformity, weight, hardness, friability and disintegration, the test that is most often associated with the assessment of *in vivo* performance is the dissolution test. Methods for comparing *in vitro* dissolution profiles can be classified into three main groups: ANOVA-based statistical methods, model-independent and model-dependent approaches. ANOVA-based methods can be classified as one way analysis of variance (ANOVA) and multivariate analysis of variance (MANOVA), which assess the difference between the means of two drug release data sets at a single point of dissolution and at multiple time points of dissolution, respectively [2]. Many studies have shown that ANOVA-based methods were overly discriminating and that it was difficult to distinguish between two dissolution curves [17-19].

*Address correspondence to this author at the Cátedra de Calidad de Medicamentos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 (1113) CABA, Argentina; Tel: 54-11-45083643; E-mail: aseggall@ffybu.uba.ar

All the model-dependent methods use some kind of curve fitting procedure. Different mathematical fit functions were investigated: the zero and first-order, Hixson-Crowell, Higuchi, quadratic, Weibull, Gompertz and logistic [2, 17-19]. Model-dependent methods investigate the mathematical equations that describe the release profile in function of some parameters related to the pharmaceutical dosage forms so the quantitative interpretation of the values is easier. These methods seem to be useful in the formulation-development stage.

The model-independent approaches produce a single value from a dissolution profile, providing direct comparisons of the dissolution data. Consequently the results do not depend on the selection of the specific parameter for fitting data but on the chosen sampling time. The model-independent methods include ratio test and the fit factors. Ratio test are performed as ratios of percent drug dissolved, area under the dissolution curve (AUC), and mean dissolution times (MDT) of the reference formulation with those of a test formulation at the same sampling time. Moore and Flanner [20] developed a simple model independent approach using fit factors. Fit factors include a difference factor f_1 , and a similarity factor f_2 . These fit factors compare the difference between the percent drug dissolved per unit time for a test and a reference formulation. Fit factors were adopted by FDA Center for Drug Evaluation and Research (CDER) [21] and the similarity factor was also adopted by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) [22] as an assessment criterion of similarity between two *in vitro* dissolution profiles. In Argentina, there is a Disposition to evaluate changes in the post marketing stage and to evaluate dissolution profiles using similarity factor f_2 [23].

In our country, Maggio *et al.* have studied eight lots of Furosemide tablets of three different brands. Brand A was considered the innovator. The lots of Brands B and C complied the requirements for the evaluation of similarity and difference respect with Brand A, although there was difference between them [24]. Also, Ruiz *et al.*, studied eleven Brands of our market. Compared with Brand A (reference product), there were three brands which differ in the similarity factor [25].

The aim of the present study was to evaluate and compare the dissolution profile of nine commercial products containing Furosemide 40 mg. marketed in Argentina, on the basis of their *in vitro* dissolution characteristics using USP, Test 1, Apparatus 2. Each

formulation was compared with the reference using model-dependent methods: the zero and first-order and model-independent methods: fit factors, mean dissolution time (MDT) and dissolution efficiency % (DE).

MATERIALS AND METHODS

Reagents

Analytical grade monobasic potassium phosphate (Anedra, Argentine) and sodium hydroxide (Mallinckrodt, USA) were used.

Furosemide was purchased in Saporiti (Argentine), 99.88%, calculated with reference to the dried substance, origin India

Materials

In our study, nine commercial tablets containing Furosemide 40 mg were purchased from pharmacies in Buenos Aires (Argentina). All tests were performed within products expiration dates.

Apparatus and Procedure

All dissolution studies were performed using USP37, Test 1 [26] Apparatus 2 in a Sotax AT7 (Sotax AG, Basel Switzerland), which is a manual-sampling dissolution bath. The furosemide tablets test was performed at 50 ± 1 rpm. The dissolution medium was monobasic potassium phosphate pH: 5.8 at 37 ± 0.5 °C. The acceptance criterion set was $Q=80$ in 60min (Test 1).

Dissolution media volume was 900 ml. In all experiments, 5 ml sample aliquots were withdrawn at 5, 15, 30, 45 and 60 min using micropipettes. The withdrawn amounts were adjusted in the calculations. All samples were filtered through filter paper (Whatman 91; 10.0 μ m). The filter paper used was properly validated using the standard solution and comparing with membrane filters. The amount dissolved was determined spectrophotometrically in a UV-VIS Spectrophotometer Cary 1E Varian (Victoria, Australia) at 274 nm.

Twelve tablets or capsules of each preparation were studied to obtain statistically significant results.

Comparative Dissolution

Model-Dependent Methods

Mathematical models have been used extensively for the parametric representation of dissolution data.

Furosemide release kinetics was analyzed by different mathematical models included zero order and first order, considering the amounts of drug release up to 60 min.

$$\text{Zero order: } Q_t = Q_0 + K_0t \quad (1)$$

$$\text{First order: } \ln Q_t = \ln Q_0 + K_0t \quad (2)$$

Model-Independent Methods

Fit Factors

A mathematical comparison was performed by applying f_1 and f_2 . These fit factors directly compare the difference between the percent drug dissolved per unit time for a test and a reference formulation.

$$f1 = \left\{ \frac{[\sum |Rt - Tt|]}{[\sum [Rt]]} \right\} \times 100, \text{ where } t = 1 \text{ to } n \quad (3)$$

$$f2 = 50 \log \left\{ \left[1 + \frac{1}{n} \sum_{t=1}^n [(Rt - Tt)^2] \right]^{-0.5} \times 100 \right\} \quad (4)$$

(3) Difference factor

(4) Similarity factor

Where n is the number of time points, R_t is the dissolution value of the reference formulation at time t and T_t is the dissolution value of the test formulation at time t .

The similarity factor (f_2) is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) dissolution between the curves. Values of f_1 between 0 and 15 and values of f_2 between 50 and 100 are used to define equivalence of two dissolution profiles, which means an average difference of no more than 10% at the sample time points.

Dissolution Efficiency

This concept was proposed by Khan and Rhodes in 1975 [27] and is defined as follows:

$$DE\% = \frac{AUC_0^T}{Q_{100,T}} \cdot 100 \quad (5)$$

Where Q_{100} is the percentage of dissolved product, DE is then the area under the dissolution curve between time points 0 and T expressed as a percentage of the curve at maximum dissolution, Q_{100} , over the same time period.

Mean Dissolution Time

The mean dissolution time is calculated from the accumulative curves of dissolved product depending on the time [28].

$$MDT = \frac{\sum [t_i \Delta Q_i]}{Q_\infty} \quad (6)$$

Where t_i is intermediate time of the intervals of time sampled, ΔQ_i is the increase of the quantities of product dissolved in every interval of t considered and Q_∞ is the maximum of product dissolved.

The results of DE and MDT of the different Brands of furosemide tablets were compared with the reference using a two-variable t test as follows:

$$t = \frac{|\bar{X}_R - \bar{X}_T|}{S_d} \sqrt{\frac{1}{n_R} + \frac{1}{n_T}} \quad (7)$$

where \bar{X}_R and \bar{X}_T are means of the model parameters of the reference and test products, respectively, n_R and n_T are the number of measurements for the mean \bar{X}_R and \bar{X}_T , and S_d is the weighted average standard deviation as shown below

$$S_d = \sqrt{\frac{(n_R - 1)S_R^2 + (n_T - 1)S_T^2}{n_R + n_T - 2}} \quad (8)$$

Where S_R and S_T are the standard deviation of the model parameters for the reference and test products. If the calculated t values are lower than the critical value of t ($1 - \alpha/2, n_R + n_T - 2$), the two means \bar{X}_R and \bar{X}_T differ only randomly at risk level α .

RESULTS AND DISCUSSION

Dissolution of drug from oral solid dosage forms is a necessary criterion for drug bioavailability (i.e. the drug must be solubilized in the aqueous environment of the gastrointestinal tract to be absorbed). For this reason, dissolution testing of solid oral drug products has emerged as one of the most important performance test for assuring product uniformity and batch to batch equivalence. Variations of the pharmacopeia limits indicate unacceptable products [21, 22].

Table 1 summarizes the characteristics of the nine products. The products were purchased from pharmacies in Buenos Aires (Argentina). All tests were performed within products expiration dates, which were similar among brands. In this study we defined Brand I as the reference product.

Table 1: Formulation Compositions

Brand	Other Ingredients	Appearance
I	Maize starch, pregelatinized starch, magnesium stearate, lactose, colloidal silicon dioxide, talc.	White, circular, with indented line in center
II	Lactose, microcrystalline cellulose, povidone, sodium dioctyl sulfosuccinate, sodium croscarmellose, sodium lauryl sulfate, talc, aerosil, magnesium stearate.	White, circular, with indented line in center
III	Lactose, maize starch polyvinylpyrrolidone.	White, circular, with indented line in center
IV	Lactose monohydrate, maize starch, povidone K-30, sodium starch glycolate, magnesium stearate.	White, circular, with indented line in center
V	Maize starch, colloidal silicon dioxide, magnesium stearate, povidone K30, sodium starch glycolate, talc, red dye ponceau 4R.	Pink, circular, with indented line in center
VI	Lactose, sodium starch glycolate, talc, magnesium stearate, coprocessed lactose and microcrystalline cellulose.	White, circular
VII	Lactose, microcrystalline cellulose, sodium bicarbonate, sodium starch glycolate, magnesium stearate.	White, circular, with indented line in center
VIII	Coprocessed lactose and microcrystalline cellulose 80, sodium croscarmellose, colloidal silicon dioxide, magnesium stearate.	White, circular, with indented line in center
IX	Ludipress, magnesium stearate.	White, circular, with indented line in center

Table 2: Dissolution Data and Descriptive Statistics of nine Brands of Furosemide Tablets

Time (min)	Brand	mean %	RSD	Lower limit	Upper limit
5	I	43.6	27.5	28.1	61.4
	II	28.2	13.8	23.0	34.8
	III	36.5	80.0	8.0	84.0
	IV	32.2	4.8	24.9	38.8
	V	84.3	2.8	80.1	88.4
	VI	69.3	2.5	66.8	71.9
	VII	72.5	7.4	67.1	80.8
	VIII	85.9	3.0	81.8	88.7
	IX	62.0	14.4	38.4	70.2
15	I	64.9	10.6	52.8	72.6
	II	84.9	9.3	75.6	98.4
	III	75.2	15.0	39.5	94.8
	IV	86.7	7.1	78.9	98.1
	V	99.5	2.2	96.5	102.4
	VI	79.1	1.9	77.5	80.8
	VII	92.2	5.6	84.9	98.1
	VIII	101.4	0.7	100.8	102.5
	IX	92.2	3.5	86.4	99.4
30	I	80.6	7.1	71.5	92.9
	II	95.2	6.8	89.2	107.8
	III	90.6	5.3	82.5	97.4
	IV	104.7	2.2	102.2	106.9
	V	101.7	2.4	97.6	104.5
	VI	84.2	3.0	82.0	88.7
	VII	93.4	7.4	84.7	100.3
	VIII	102.2	2.4	98.6	105.9
	IX	98.2	1.3	96.4	99.7

(Table 2). Continued.

Time (min)	Brand	mean %	RSD	Lower limit	Upper limit
45	I	87.7	4.9	81.4	94.5
	II	96.2	6.6	90.6	108.4
	III	94.5	4.1	88.3	99.9
	IV	107.1	1.5	104.4	109.0
	V	104.1	1.1	103.0	106.0
	VI	86.3	3.2	83.0	90.7
	VII	93.8	7.8	85.4	102.2
	VIII	103.3	1.6	102.2	106.1
	IX	99.6	1.3	97.1	100.8
60	I	92.4	3.2	89.0	99.2
	II	96.6	5.1	92.4	105.3
	III	95.1	3.6	90.4	99.4
	IV	107.9	1.5	105.8	109.6
	V	104.3	2.1	101.5	107.7
	VI	87.7	3.0	84.2	90.2
	VII	94.3	8.4	84.5	102.8
	VIII	102.6	1.4	100.6	104.5
	IX	99.6	1.8	97.7	102.6

In the dissolution test for furosemide tablets described in the American Pharmacopeia (United States Pharmacopeia 37) no less than 85% (Q+5%) should be dissolved in 60 minutes. Table 2 summarizes the mean percent dissolved at each time point, the relative standard deviation (RSD), and the upper and lower limits.

Evaluating the dissolved percentage curves vs. time (Figure 1), it could be observed that the analyzed products presented very distinct dissolution profiles. As furosemide is a BCS IV drug, the dissolution test may be formulation dependent, and the decision related to generics must be made based on the *in vivo* bioequivalence results.




Figure 1: Dissolution profiles.

Table 3: Linearization of the Furosemide Release Profiles (Q Expressed in mg)

Brand	Zero order		First order	
	K (mg/min)	R ²	K (min ⁻¹)	R ²
I	0.3361	0.8824	-0.0360	0.9933
II	0.3983	0.5617	-0.0520	0.7930
III	0.3728	0.6990	-0.0465	0.9008
IV	0.4669	0.6455	-0.1157	0.9965
V	0.1210	0.6504	-0.0107	0.0360
VI	0.1220	0.8199	-0.0158	0.9022
VII	0.1204	0.5069	-0.0227	0.5971
VIII	0.0939	0.4958	-0.0565	0.6165
IX	0.2281	0.5838	-0.0841	0.9197

Dissolution profiles of the nine products were evaluated by fitting experimental data to zero and first kinetics order. Table 3 lists zero and first order dissolution constants (K) and determination constant (r^2) values, bold print indicating the best fits. For the nine products the curve of better adjustment was the first order. Brands 1 and IV have the best fitting, with the maximum determination coefficient. The results of the first order model for the nine brands indicate different drug release mechanism for the furosemide products.

The DE and the MDT values are a useful way to reduce each curve to a single number, which may be related to the dissolution rate constant. The average, the standard deviation (SD), the variation coefficient (CV) and t_{ex} of the DE data are presented in Table 4. Test “t” with 95% confidence for 22 degrees of freedom was ($t_{n-2, \alpha:0.05}$) = 2.0739. There was no significant difference between the reference product and Brands II, III and IV. The average, SD, CV and t_{ex} of the MDT

data are presented in Table 5. Test “t” with 95% confidence for 22 degrees of freedom was ($t_{n-2, \alpha:0.05}$) = 2.0739. There was no significant difference between the reference product and Brands II, III, IV and V.

Fit factors are important quantitative methods that have been recommended by FDA guidelines for industry for comparison of dissolution profiles [21]. Results obtained from the test using Brand I as the reference are shown in Table 6. The similarity factor f_2 is more sensitive in finding dissimilarity between dissolution curves than the difference factor f_1 , and the values of fit factors are dependent on the number of sampling time point chosen. According to FDA f_1 values up to 15 and f_2 values greater than 50 should ensure equivalence of the dissolution curves, indicating an average difference of no more than 10% at the sample time points. Based on this guideline, only Brand III seems to show a dissolution curve similar with the reference.

Table 4: Average (M), Standard Deviation (SD), Variation Coefficient (CV) and t Experimental (t_{ex}) of Dissolution Efficiency % (ED)

Brand	M	SD	CV	t_{ex}
I	74.4	2.9	3.8	
II	83.9	1.8	2.2	1.6293
III	80.2	8.2	10.3	0.3851
IV	82.1	2.3	2.8	1.2116
V	91.8	1.6	1.8	3.0707
VI	89.8	1.4	1.6	2.7727
VII	92.7	1.6	1.7	3.2399
VIII	93.7	0.6	0.7	3.8096
IX	89.8	2.9	3.2	2.1882

Table 5: Average (M), Standard Deviation (SD), Variation Coefficient (CV) and t_{ex} Experimental (t_{ex}) of Mean Dissolution Time (MDT)

Brand	M	SD	CV	t_{ex}
I	20.4	2.0	9.6	
II	14.2	1.2	8.7	1.5382
III	16.8	6.1	36.3	0.3244
IV	14.2	1.2	8.7	1.5382
V	15.5	1.6	10.4	1.1124
VI	9.4	1.0	10.1	2.9185
VII	7.4	1.0	14.0	3.3838
VIII	6.7	0.4	6.6	3.9479
IX	10.2	1.6	15.4	2.3430

Table 6: Fit Factors for the Nine Brands of Furosemide Tablets Based on The Average of Twelve Tablets

Brand	Fit Factor	
	f_1	f_2
I/II	17.0	43.1
I/III	10.0	54.3
I/IV	25.3	36.1
I/V	33.8	28.4
I/VI	10.2	43.9
I/VII	20.9	36.4
I/VIII	34.2	27.7
I/IX	22.3	37.7

CONCLUSION

This study found variations in the dissolution profiles of furosemide tablets commonly available in Argentina. The analyzed products presented very distinct dissolution profiles, showing that the dissolution test may be formulation dependent. All Brands fulfill the specifications of dissolution test of USP 37.

The kinetic curve of better adjustment was the first order. Brands I and IV have the best fitting, with the maximum determination coefficient. There is no significant difference in DE among the reference product and Brands II, III and IV. There is not significant difference in MDT between the reference product and Brands II, III, IV and V.

Using fit factors, only Brands I and III were similar.

In conclusion, significant differences were seen between the *in vitro* dissolution profiles of furosemide

tablets from various commercial preparations. Unless, it has been demonstrated *in vivo* bioequivalence of furosemide market products interchangeability with generics should be avoided.

ACKNOWLEDGEMENT

This work was supported by grant 20020100100816 from UBA and PIP N°: 11420110100380 from CONICET both to A. I. Segall.

REFERENCES

- [1] Perioli L, D'Alba G, Pagano C. New oral solid dosage form for furosemide oral administration. *Eur J Pharm Biopharm* 2012; 80: 621-9. <http://dx.doi.org/10.1016/j.ejpb.2011.12.011>
- [2] Khan F, Li M, Schindwein W. Comparison of *in vitro* dissolution tests for commercially available aspirin tablets. *Diss Technol* 2013; 20: 48-58.
- [3] Disposición N° 4788 (ANMAT), Buenos Aires, Argentina, 15 de Agosto de 2012.
- [4] Granero GE, Longhi MR, Mora MJ, *et al.* Biowaiver monographs for immediate release solid oral dosage forms: Furosemide. *J Pharm Sci* 2010; 99: 2544-56. <http://dx.doi.org/10.1002/jps.22030>
- [5] Doherty C, York P. Evidence for solid- and liquid-state interactions in a furosemide-polyvinylpyrrolidone solid dispersion. *J Pharm Sci* 1987; 76: 731-7. <http://dx.doi.org/10.1002/jps.2600760912>
- [6] Akbuga J, Gürsoy A, Yetimoglu F. Preparation and properties of tablets prepared from furosemide-PVP solid dispersion systems. *Drug Dev Ind Pharm* 1988; 14: 2091-108. <http://dx.doi.org/10.3109/03639048809152004>
- [7] Ozdemir N, Ordu S. Improvement of dissolution properties of furosemide by complexation with beta-cyclodextrin. *Drug Dev Ind Pharm* 1998; 24: 19-25. <http://dx.doi.org/10.3109/03639049809082348>
- [8] Shin SC, Oh IJ, Lee YB, Choi HK, Choi JS. Enhanced dissolution of furosemide by coprecipitating or cogrinding with croscopvidone. *Int J Pharm* 1998; 175: 17-24. [http://dx.doi.org/10.1016/S0378-5173\(98\)00260-9](http://dx.doi.org/10.1016/S0378-5173(98)00260-9)

- [9] Shin SC, Kim J. Physicochemical characterization of solid dispersion of furosemide with TPGS. *Int J Pharm* 2003; 251: 79-84.
[http://dx.doi.org/10.1016/S0378-5173\(02\)00586-0](http://dx.doi.org/10.1016/S0378-5173(02)00586-0)
- [10] Farcas A, Jarroux N, Farcas AM, Harabagiu V, Guegan P. Synthesis and characterization of furosemid complex in b-cyclodextrin. *Dig J Nanomater Bios* 2006; 1: 55-60.
- [11] Kaukonen AM, Laitinen L, Salonen J, *et al.* Enhanced *in vitro* permeation of furosemide loaded into thermally carbonized mesoporous silicon (TCPSi) microparticles. *Eur J Pharm Biopharm* 2007; 66: 348-56.
<http://dx.doi.org/10.1016/j.ejpb.2006.11.021>
- [12] Patel RP, Patel DJ, Bhimani DP, Patel JK. Physicochemical characterization and dissolution study of solid dispersions of furosemide with polyethylene glycol 6000 and polyvinyl pyrrolidone K30. *Diss Technol* 2008; 15: 17-25.
- [13] Chaulang G, Patel P, Hardikar S, Kelkar M, Bhosale A, Bhise S. Formulation and evaluation of solid dispersions of furosemide in sodium starch glycolate. *Trop J Pharm Res* 2009; 8: 43-51.
<http://dx.doi.org/10.4314/tjpr.v8i1.14711>
- [14] Zvonar A, Berginc K, Kristl A, Gašperlin M. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. *Int J Pharm* 2010; 388: 151-8.
<http://dx.doi.org/10.1016/j.ijpharm.2009.12.055>
- [15] Perioli L, Ambrogi V, Nocchetti M, Sisani M, Pagano C. Preformulation studies on host-guest composites for oral administration of BCS class IV drugs: HTIc and furosemide. *Appl Clay Sci* 2011; 53: 696-703.
<http://dx.doi.org/10.1016/j.clay.2011.06.006>
- [16] De Zordi N, Monaghan M, Kikic I, *et al.* Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions. *Eur J Pharm Biopharm* 2012; 81: 131-41.
<http://dx.doi.org/10.1016/j.ejpb.2012.01.002>
- [17] Yuksel N, Kanik AE, Baykara T. Comparison of *in vitro* dissolution profiles by ANOVA-based, model-dependent and -independent methods. *Int J Pharm* 2000; 209: 57-67.
[http://dx.doi.org/10.1016/S0378-5173\(00\)00554-8](http://dx.doi.org/10.1016/S0378-5173(00)00554-8)
- [18] Polli JE, Rekhi GS, Ausburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. *J Pharm Sci* 1997; 86: 690-700.
<http://dx.doi.org/10.1021/js960473x>
- [19] Costa FO, Sousa JJS, Pais AACC, Formosinho SJ. Comparison of dissolution profiles of Ibuprofen pellets. *J Control Release* 2003; 89: 199-212.
[http://dx.doi.org/10.1016/S0168-3659\(03\)00033-6](http://dx.doi.org/10.1016/S0168-3659(03)00033-6)
- [20] Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. *Pharm Technol* 1996; 20: 64-74.
- [21] Guidance for the industry: dissolution testing of immediate release solid oral dosage forms, FDA, Center for Drug Evaluation and Research, Rockville, MD, 1997.
- [22] Guideline on the investigation of bioequivalence: EMA, Committee for Medicinal Products for Human Use (CHMP), London, UK, 2010.
- [23] Disposición N° 5568 (ANMAT), Buenos Aires, Argentina, 5 de Febrero de 2009.
- [24] Maggio RM, Castellano PM, Kaufman TS. A new principal component analysis-based approach for testing "similarity" of drug dissolution profiles. *Eur J Pharm Sci* 2008; 34: 66-77.
<http://dx.doi.org/10.1016/j.ejps.2008.02.009>
- [25] Ruiz ME, Gregorini A, Talevi A, Volonté MG. Dissolution studies of generic medications: New evidence of deviations from the Transitivity principle. *Diss Technol* 2012; 19: 13-24.
- [26] The United States Pharmacopeia 37th Ed.) U.S. Pharmacopeial Convention, Rockville, MD; 2014, 3104-3105.
- [27] Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of direct compression systems. *Pharm Acta Helv* 1972; 47: 594-607.
- [28] Aguilar Ros A, Caamaño Somoza M, Martín Martín FR, Montejo Rubio MC. Parámetros amodelísticos: comparación de perfiles. In *Biofarmacia y Farmacocinética, ejercicios y problemas resueltos*, 1st ed. Elsevier España S. L., Barcelona, España, 2008; pp. 3-4.

Received on 17-11-2014

Accepted on 26-11-2014

Published on 17-12-2014

DOI: <http://dx.doi.org/10.6000/1929-5030.2014.03.04.1>